127 related articles for article (PubMed ID: 14727226)
1. How much evidence do we have to recommend oral doxycycline for empirical treatment of community-acquired pneumonia?
Bantar C
Clin Infect Dis; 2004 Feb; 38(3):459-60. PubMed ID: 14727226
[No Abstract] [Full Text] [Related]
2. Short-course beta-lactam treatment for community-acquired pneumonia.
Stralin K; Sjöberg L; Holmberg H
Clin Infect Dis; 2004 Mar; 38(5):766-7. PubMed ID: 14986269
[No Abstract] [Full Text] [Related]
3. Doxycycline for nursing home acquired pneumonia (NHAP).
Cunha BA
Scand J Infect Dis; 2009; 41(1):77-8, author reply 76. PubMed ID: 18821134
[No Abstract] [Full Text] [Related]
4. [New quinolones for the treatment of community-acquired pneumonia--pro].
Zimmerli S
Dtsch Med Wochenschr; 2003 May; 128(19):1070. PubMed ID: 12736859
[No Abstract] [Full Text] [Related]
5. [New quinolones for the treatment of community-acquired pneumonia--contra].
Egger M
Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
[No Abstract] [Full Text] [Related]
6. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002).
Jones RN; Sader HS; Fritsche TR
Diagn Microbiol Infect Dis; 2004 Jun; 49(2):147-9. PubMed ID: 15183865
[TBL] [Abstract][Full Text] [Related]
7. Doxycycline for community-acquired pneumonia.
Cunha BA
Clin Infect Dis; 2003 Sep; 37(6):870. PubMed ID: 12955665
[No Abstract] [Full Text] [Related]
8. [Initial empirical antibiotic treatment of community-acquired pneumonia].
Frías J; Gomis M; Prieto J; Mensa J; Bouza E; García-Rodríguez JA; Torres A; Dorca J; Zalacaín R; García de Lomas J
Rev Esp Quimioter; 1998 Sep; 11(3):255-61. PubMed ID: 9795313
[No Abstract] [Full Text] [Related]
9. Doxycycline for treatment of community-acquired pneumonia.
Johnson JR
Clin Infect Dis; 2002 Sep; 35(5):632; author reply 632-3. PubMed ID: 12173142
[No Abstract] [Full Text] [Related]
10. [Management of adult patients with community-acquired pneumonia. Evidence-based guidelines from the Swedish Infectious Diseases Association].
Strålin K; Goscinski G; Hedlund J; Lidman C; Spindler C; Ortqvist A; Holmberg H
Lakartidningen; 2008 Sep 17-23; 105(38):2582-7. PubMed ID: 18846863
[No Abstract] [Full Text] [Related]
11. [Community-acquired pneumonia--treatment perspectives in the physician's office].
Ewig S
MMW Fortschr Med; 2004 May; 146(21):43-5. PubMed ID: 15373084
[TBL] [Abstract][Full Text] [Related]
12. [Management of lower respiratory tract infections in immunocompetent adults (community-acquired pneumonia and acute exacerbation of chronic obstructive pulmonary disease): the challenge of a new consensus conference].
Chidiac C
Med Mal Infect; 2006 Jan; 36(1):1-3. PubMed ID: 16413722
[No Abstract] [Full Text] [Related]
13. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
Feldman C
J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG
Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
Echols RM; Tillotson GS; Song JX; Tosiello RL
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial resistance and treatment of community-acquired pneumonia.
Mandell LA
Clin Chest Med; 2005 Mar; 26(1):57-64. PubMed ID: 15802166
[TBL] [Abstract][Full Text] [Related]
17. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
Gilbert DN
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S121-2. PubMed ID: 18986276
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of community-acquired pneumonia--treatment].
Andersen LV; Brock B; Jakobsen P; Nielsen LP
Ugeskr Laeger; 2008 Jan; 170(3):127-30. PubMed ID: 18208726
[TBL] [Abstract][Full Text] [Related]
19. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
20. Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae.
Lee WK; Young BW
J Antimicrob Chemother; 2005 Sep; 56(3):603-5. PubMed ID: 16040621
[No Abstract] [Full Text] [Related]
[Next] [New Search]
